FILE PHOTO: A bottle of Zantac heartburn drug is seen on this image illustration taken October 1, 2019. REUTERS/Brendan McDermid/Illustration/File Photograph
(Reuters) – The U.S. Meals and Drug Administration mentioned on Wednesday that alternate options to fashionable heartburn drug Zantac and its generic variations, identified chemically as ranitidine, haven’t been discovered to comprise the possible cancer-causing impurity that ranitidine has been linked to. (bit.ly/2oYJ1Vz)
U.S. retailers Walmart Inc, CVS Well being Corp Walgreens Boots Alliance Inc and Ceremony Assist Corp have all eliminated Zantac off their cabinets after some medicine containing its key ingredient ranitidine had been discovered to have traces of the impurity, N-nitrosodimethylamine (NDMA).
Early assessments of alternate options to over-the-counter ranitidine, reminiscent of Pepcid, Tagamet, Nexium, Prevacid and Prilosec present no NDMA, the company mentioned.
The FDA mentioned earlier this month it discovered unacceptable ranges of NDMA in medicine containing ranitidine. The regulator requested ranitidine makers to conduct their very own testing to evaluate ranges of the impurity and to ship samples of their merchandise for testing by the company.
French drugmaker Sanofi SA final week mentioned it will recall Zantac in the US and Canada.
NDMA had beforehand been present in some blood stress medicines from a category of medicine often known as angiotensin II receptor blockers, or ARBs. The possibly cancer-causing impurities are believed to have been launched by current modifications within the manufacturing course of for the medicine.
Reporting by Manojna Maddipatla in Bengaluru; Modifying by Shailesh Kuber